Cryo-EM Reveals How the ATR Checkpoint Kinase Flips Its Molecular Switch

Every time a human cell copies its DNA, it gambles with its own genome. Forks stall, lesions block polymerases, and fragile stretches of the double helix threaten to snap apart. The cell’s answer to this daily crisis is the ATR–ATRIP kinase complex, the master regulator of the replication stress response and a heavily pursued drug target in oncology. Now, a team of structural biologists led by Shuai Qiao and Jingdong Cheng has captured the human ATR–ATRIP machine in unprecedented molecular detail, freezing it in a gallery of functional states that spans quiet standby, active catalysis, and drug-bound shutdown. Publishing in Nature Structural & Molecular Biology, the group used high-resolution cryo-electron microscopy to image the complex bound to its nucleotide fuel, its substrate Chk1, its activator TopBP1, and four clinical ATR inhibitors. The resulting structures read like a molecular instruction manual for how the cell’s replication checkpoint is switched on — and how cancer drugs can jam it.

ATR, short for ataxia-telangiectasia and Rad3-related, belongs to the PIKK family of giant kinases that also includes ATM, DNA-PKcs, mTOR and SMG1. Like its siblings, ATR is an enormous HEAT-repeat scaffold carrying a kinase domain buried deep within, and it operates as a dimer paired with its obligate partner ATRIP. Since the first cryo-EM structures of human ATR–ATRIP appeared in 2018, researchers have known the complex’s overall architecture but not the physical choreography of its activation. The central puzzle has been phosphorylation: ATR autophosphorylates itself, and this modification is considered a hallmark of the active kinase, yet nobody had seen structurally what phosphorylation does to the machine or how the activator protein TopBP1 drives the process. The new study addresses that gap directly by trapping the complex at successive stages of its catalytic cycle.

The team began with precatalytic snapshots. In two structures determined with the non-hydrolysable ATP analogue ATPγS wedged in the active site, they found that nucleotide binding alone accomplishes something remarkable: it primes the catalytic center for chemistry without wholesale rearrangement of the kinase domain. When the researchers then added a fragment of Chk1, the key downstream effector of the ATR pathway, the substrate docked neatly onto the primed enzyme. In other words, ATP binding and substrate positioning can proceed as relatively independent, modest steps rather than requiring a dramatic conformational detonation. This finding revises the textbook expectation that PIKK kinases need massive global movements to become catalytically competent, and it suggests that the rate-limiting event in ATR activation lies elsewhere — specifically, in the regulatory rearrangements triggered by TopBP1.

That TopBP1-dependent rearrangement is the structural centerpiece of the paper. In the activated structure, two molecules of TopBP1 bind simultaneously to the ATR–ATRIP dimer, one engaging each protomer from opposite faces. TopBP1 latches onto the HEAT-repeat scaffold far from the active site, and in doing so it locks the N-HEAT and M-HEAT domains of ATR together in both protomers. In the precatalytic and substrate-bound states, these scaffold elements make intimate contact in one protomer while hovering apart in the other — an inherent asymmetry. TopBP1 binding abolishes that asymmetry, snapping the dimer into a near-symmetric conformation that promotes ATR–ATRIP autophosphorylation and drives efficient phosphorylation of Chk1. Detailed atomic contacts reveal how this is achieved: an intensive network of hydrogen bonds welds a TopBP1 beta strand to the M-HEAT domain, the tryptophan residue W1145 of TopBP1 buries into a hydrophobic pocket at the N-HEAT/M-HEAT junction, and salt-bridge interactions fasten a TopBP1 helix onto the N-HEAT superhelix.

Perhaps the most provocative observation concerns what happens after activation. The researchers purified ATR–ATRIP complexes that had been fully autophosphorylated in the presence of TopBP1, then stripped the activator away and determined the structure of the phosphorylated kinase on its own. Remarkably, the phosphorylated complex remained fully competent to phosphorylate Chk1, and it did so regardless of how much TopBP1 was added back. Structurally, the released enzyme adopted an asymmetric conformation, yet its kinase domain was essentially indistinguishable from that of the TopBP1-bound, near-symmetric activated state. The authors conclude that catalytic activity is compatible with both near-symmetric and asymmetric architectures, meaning that phosphorylation — not a rigid, TopBP1-imposed symmetry — is the true durable switch. Once ATR has phosphorylated itself, the checkpoint engine keeps running even if its ignition key is removed, a property with clear implications for how sustained checkpoint signaling is maintained at damaged replication forks.

The autophosphorylation story was reinforced biochemically. Mass spectrometry mapped dozens of newly phosphorylated sites on ATR and ATRIP, and phosphatase treatment confirmed that the mobility shifts seen in gels were genuinely phosphorylation-dependent. Activity assays showed a clean dose-response: non-phosphorylated ATR–ATRIP phosphorylated Chk1 only when TopBP1 was titrated in, whereas the pre-phosphorylated complex catalyzed Chk1 modification at TopBP1 concentrations approaching zero. Interestingly, an isolated ATR head domain displayed only basal activity with or without TopBP1, underscoring that the full dimeric scaffold — and its TopBP1-driven reorganization — is required to reach full catalytic power. Together these experiments elevate ATR autophosphorylation from a correlative biomarker to a mechanistically demonstrated molecular switch for checkpoint activation.

The paper’s second act concerns therapy. ATR inhibitors such as berzosertib (VX-970/M6620), ceralasertib (AZD6738), gartisertib (VX-803/M4344) and elimusertib (BAY 1895344) are in clinical development as sensitizers that push tumor cells with pre-existing DNA repair defects over the edge. The team determined four separate inhibitor-bound structures of ATR–ATRIP, one for each compound, providing the first side-by-side atomic views of how this pharmacological class occupies the ATR active site. The nucleotide-binding pocket turns out to be divisible into four sub-compartments: an adenine-binding pocket lined by residues including M2325, Y2365, I2377, W2379 and V2380; an inner hydrophobic pocket; a ribose-binding site; and a triphosphate-binding site. All four inhibitors anchor themselves in the adenine pocket, but each then exploits the pocket’s flexibility differently, extending flanking chemical groups into the hydrophobic cavity, the ribose site, or the triphosphate region.

These structures explain both potency and selectivity. ATR’s adenine and hydrophobic sub-pockets are shifted toward the C-lobe relative to the corresponding sites in DNA-PKcs, mTOR and ATM, a displacement caused by the bulky side chains of M2325 and V2493 in ATR. Inhibitors can therefore nestle into an ATR-specific geometry that the closely related PIKK kinases cannot accommodate. Superimposition with structures of DNA-PKcs, mTOR and ATM further showed that a key hydrogen bond formed by berzosertib with glycine 2385 of ATR would be sterically blocked by the larger residues occupying the equivalent positions in the sibling kinases. In effect, the drugs exploit the conformational plasticity of the ATR active site — the very same flexibility that allows ATPγS to prime the kinase — to achieve multipocket engagement that favors ATR over its family members. For medicinal chemists, the four structures amount to a comparative map of which sub-pockets each clinical candidate touches, a starting grid for designing next-generation inhibitors with improved selectivity and resistance profiles.

Taken together, the study delivers a structural framework in which ATR regulation can finally be read as a sequence of physically defined events. ATP binding primes the catalytic cleft and positions Chk1; TopBP1 binding to the HEAT scaffold reorganizes the dimer and licenses autophosphorylation; phosphorylation converts the enzyme into a durably active state that survives TopBP1 dissociation; and small molecules shut the whole system down by wedging into the plastic ATP pocket. The work also resonates with parallel findings on ATM, where asymmetric activation of the dimeric kinase has recently been visualized, hinting at shared regulatory logic across the PIKK family. For cancer biology, the implications are tangible: tumors rely obsessively on ATR to survive their own replication chaos, and a structure-level understanding of both the activation switch and the drug-binding pocket should accelerate the design of inhibitors that hit ATR harder and more selectively. As ATR inhibitors advance through clinical trials, the molecular movie assembled by Wang, Cheng, Qiao and colleagues provides the kind of mechanistic blueprint on which the next generation of checkpoint-targeted therapies can be drawn.

Subject of Research: Cryo-EM structural mechanisms of phosphorylation-driven activation and inhibitor binding of the human ATR–ATRIP checkpoint kinase complex

Article Title: Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR–ATRIP

Article References: Wang, L., Wang, M., Zhao, L., Rao, Q., Wu, H., Ma, B., Wang, J., Zheng, J., Li, Y., Xu, Y., Guo, J., Cheng, J., & Qiao, S. (2026). Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR–ATRIP. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01887-4

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01887-4

Keywords: ATR, ATRIP, TopBP1, Chk1, cryo-electron microscopy, DNA damage response, replication stress, autophosphorylation, kinase activation, ATR inhibitors, berzosertib, cancer therapy